VGXI New Manufacturing Facility

December 3, 2019

VGXI Selects BE&K As Design-Build Partner for New Manufacturing Facility

BE&K Building Group has been selected as VGXI’s Design-Build Partner for a new biopharmaceutical manufacturing facility, the initial phase of VGXI’s future campus master plan. The planned 240,000-square-foot facility will include expanded manufacturing capabilities and multiple flexible production suites to support both DNA- and RNA-based biopharmaceuticals at all phases of development through commercial supply. VGXI, Inc. is a leading provider of manufacturing and development services for DNA vaccines and gene therapies.

“The choice of BE&K is based on their strong reputation and extensive experience serving advanced manufacturing businesses, especially within the biotech industry. We look forward to a productive partnership as we move forward with the first phase of our company’s facility expansion.”

— GXI CEO Young Park

According to market reports, the gene therapy industry is rapidly gaining momentum as recent approvals pave the way for a new wave of revolutionary medicines. A driving factor for both site selection and building design is available capacity to support VGXI’s continued, future expansions to meet growing industry demand. VGXI has identified and selected a suitable location for their future campus in Conroe, Texas, with the local government recently providing a $1.2 million incentive.

Design of the first phase of the site is underway, with projected completion of the first manufacturing facility within 2 to 3 years.